loader from loading.io

Episode 437: Remembering David Mitchell

RealTalk MS

Release Date: 01/12/2026

Episode 447: Walking with Many Sisters Toward a Cure with Brigitte Delaney show art Episode 447: Walking with Many Sisters Toward a Cure with Brigitte Delaney

RealTalk MS

In 1988, there were just 42 Walk MS events, raising approximately $4 million. In 2025, there were 170 events across the country that raised over $30 million. As the largest private funder of MS research in the world, the National MS Society relies on funds raised at events like Walk MS to continue supporting the work that brings us closer to cures.   This week, Brigitte Delaney, an amazing fundraiser and captain of the Many Sisters Walk MS team, shares her story, talks about the origin of the Many Sisters team, and offers her recipe for successful fundraising. We're also sharing...

info_outline
Episode 446: MS Advocacy and the National MS Society's Public Policy Conference with Steffany Stern show art Episode 446: MS Advocacy and the National MS Society's Public Policy Conference with Steffany Stern

RealTalk MS

175 MS activists are heading to Washington, D.C. next week for the National MS Society’s Public Policy Conference. Their mission: to bring the concerns of the MS community directly to lawmakers on Capitol Hill.  When it comes to the legislative support for healthcare and medical research, it's no secret that these are unusual times. Joining me to brief us on the National MS Society's ongoing advocacy efforts and give us a sneak peek at the specific legislative issues we'll be taking to Capitol Hill is the National MS Society's Vice President of Advocacy, Steffany Stern. We'll...

info_outline
Episode 445: It's MS Awareness Week with Kristine Werner Ozug and Kim, Kim, and Kim show art Episode 445: It's MS Awareness Week with Kristine Werner Ozug and Kim, Kim, and Kim

RealTalk MS

It’s MS Awareness Week, and this year we’re diving into a theme that hits home for millions: Unseen MS. Multiple sclerosis is a master of disguise; it can be entirely invisible to the naked eye while remaining profoundly life-altering for the person living it. In this episode, we’re exploring the spectrum of the MS experience through two distinct, yet deeply connected stories.  First, you'll hear from RealTalk MS team member Kristine Werner Ozug. Kristine shares what it’s like to navigate a world that doesn’t always see her struggle, and how her "mostly invisible"...

info_outline
Episode 444: Treating MS with a GLP-1 with Dr. Ellen Mowry show art Episode 444: Treating MS with a GLP-1 with Dr. Ellen Mowry

RealTalk MS

You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes and promoting weight loss, researchers are finding that these drugs are also effective in a broad range of other health conditions. So, what about MS? My guest this week is Dr. Ellen Mowry, the principal investigator of a clinical trial to determine whether a GLP-1 drug can reduce brain inflammation and provide neuroprotection in people living with progressive MS. We're sharing details...

info_outline
Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith show art Episode 443: The 2026 ACTRIMS Forum (Part 3) with Dr. Helen Tremlett, Dr. Ilana Katz Sand, and Kathy Smith

RealTalk MS

Welcome back to the third and final part of our coverage of the 2026 ACTRIMS Forum. This week's episode bridges the gap between groundbreaking clinical research and the nuanced reality of living with MS every day. First, we'll dive into the "before" and "after" of a diagnosis, starting with Dr. Helen Tremlett’s insights into the MS prodrome—those subtle, early signs that appear years before typical MS symptoms. We'll also talk with Dr. Tremlett about how other health conditions can predict long-term outcomes in sometimes surprising ways.   Dr. Ilana Katz Sand shares her latest...

info_outline
Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug show art Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

RealTalk MS

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest information on stem cell transplantation to evolving treatment strategies to the labels used to describe MS, we’re breaking down the complex science into the conversations that matter most to the MS community.   Joining me to discuss one of the most significant presentations from the 2026 ACTRIMS Forum is Dr. Jeffrey Cohen, who opened the event with the Kenneth P. Johnson Memorial...

info_outline
Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu show art Episode 441: The 2026 ACTRIMS Forum with Dr. Manuel Friese, Dr. Amit Bar-Or, and Dr. Haritha Desu

RealTalk MS

Last week, over 1,400 scientists and clinicians gathered in San Diego, California, at the 2026 Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting, better known as the ACTRIMS Forum.  This week, in Part One of our coverage, you'll hear from three of the experts who presented their research at the ACTRIMS Forum.   Dr. Manuel Friese, a clinician-scientist at the Institute of Neuroimmunology and Multiple Sclerosis at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany, where he serves as the Director of the Center for Molecular...

info_outline
Episode 440: An MS Specialist's Response to the FDA with Dr. William Conte show art Episode 440: An MS Specialist's Response to the FDA with Dr. William Conte

RealTalk MS

This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investigational disease-modifying therapies to undergo FDA review.    A Complete Response Letter is an official letter from the FDA to a drug manufacturer stating that the agency can't approve a new medicine in its current form. It's not an outright "no" that kills a project; it's more like a "not yet." However, this Complete Response Letter raised some issues which, at first...

info_outline
Episode 439: Preventing MS with Dr. Bruce Bebo show art Episode 439: Preventing MS with Dr. Bruce Bebo

RealTalk MS

The first coordinated global research strategy to prevent MS has been announced. This week, Dr. Bruce Bebo, the National MS Society's Executive Vice President and Chief Research & Medical Affairs Officer, joins me to explain what MS prevention looks like and how experts plan to achieve this remarkable goal. We'll also tell you who won the 2025 Barancik Prize for Innovation in MS Research, and we'll explain how their groundbreaking research impacts MS care. We're sharing the details of a newly announced partnership designed to reduce delays in getting an MS diagnosis and expand...

info_outline
Episode 438: The Discovery of 2 MS Subtypes with Dr. Arman Eshaghi show art Episode 438: The Discovery of 2 MS Subtypes with Dr. Arman Eshaghi

RealTalk MS

One of the more confusing aspects of MS is that it can present differently from one person to the next. A research team at University College London may have uncovered a reason for that when they identified two new, and quite different, subtypes of MS.    Joining me to walk us through this discovery and to explain how it may impact MS clinical care is the study's principal investigator, Dr. Arman Eshaghi. We're also sharing study results that may explain how the Epstein-Barr Virus triggers MS in some individuals. We'll tell you about the free online fitness and wellness...

info_outline
 
More Episodes
I don't have to remind anyone who listens to this podcast that the cost of MS disease-modifying therapies is obscenely high. And we're not just talking about relatively new medications. Older medications -- some decades old -- continue to increase in price without any rational explanation for why or how.
 
On January 2nd, we lost a true warrior in the ongoing battle to lower the price of prescription drugs when David Mitchell, the founder of Patients for Affordable Drugs, passed away.
 

David Mitchell

I met David in 2018 at a National MS Society Public Policy Conference, and he was a guest on Episode 31 of RealTalk MS.  This week, I'm re-sharing the conversation we had in 2018.

We'll also tell you about an international workshop that represents the initial steps in developing a global research agenda to end MS.

We're explaining how AI is about to have a major impact on healthcare.

And we'll share the American Medical Association's brief to Congress, making the case for extending access to telehealth.

We have a lot to talk about! Are you ready for RealTalk MS??!


This Week: We're remembering David Mitchell  :22

The first steps toward a global research agenda to prevent MS were just published  1:02

Doctor AI will see you now  5:45

The American Medical Association asks lawmakers to extend access to telehealth  10:27

David Mitchell in his own words  12:41

Share this episode  27:56

Next week  28:16


SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/437

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!


LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Patients for Affordable Drugs
https://patientsforaffordabledrugs.org

PAPER: Toward a Global Research Agenda for Preventing Multiple Sclerosis
https://journals.sagepub.com/doi/10.1177/13524585251398381

AMA BRIEF: The Case for Permanent Telehealth Policy and Expanded Access to Virtual Care
https://ama-assn.org/system/files/issue-brief-telehealth-policy-expanded-access-to-virtual-care.pdf

ChatGPT Health
https://openai.com/index/introducing-chatgpt-health

JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review


Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 437
Guests: David Mitchell